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INTRODUCTION: Results from our laboratory have demonstrated that intracerebroventricular administration of
sildenafil to conscious rats promoted a noticeable increase in both lumbar sympathetic activity and heart rate, with
no change in the mean arterial pressure. The intracerebroventricular administration of sildenafil may have
produced the hemodynamic effects by activating sympathetic preganglionic neurons in the supraspinal regions and
spinal cord. It is well documented that sildenafil increases intracellular cGMP levels by inhibiting phosphodiesterase
type 5 and increases cAMP levels by inhibiting other phosphodiesterases.
OBJECTIVE: To examine and compare, in conscious rats, the hemodynamic response following the intrathecal
administration of sildenafil, 8-bromo-cGMP (an analog of cGMP), forskolin (an activator of adenylate cyclase), or
dibutyryl-cAMP (an analog of cAMP) in order to elucidate the possible role of the sympathetic preganglionic
neurons in the observed hemodynamic response.
RESULTS: The hemodynamic responses observed following intrathecal administration of the studied drugs
demonstrated the following: 1) sildenafil increased the mean arterial pressure and heart rate in a dose-dependent
manner, 2) increasing doses of 8-bromo-cGMP did not alter the mean arterial pressure and heart rate, 3) forskolin
did not affect the mean arterial pressure but did increase the heart rate and 4) dibutyryl-cAMP increased the mean
arterial pressure and heart rate, similar to the effect observed following the intrathecal injection of the highest dose
of sildenafil.
CONCLUSION: Overall, the findings of the current study suggest that the cardiovascular response following the
intrathecal administration of sildenafil to conscious rats involves the inhibition of phosphodiesterases other than
phosphodiesterase type 5 that increase the cAMP level and the activation of sympathetic preganglionic neurons.
KEYWORDS: Sympathetic preganglionic neurons; Lumbar sympathetic activity; Forskolin; Phosphodiesterase 5;
Spinal cord.
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INTRODUCTION
Previous results from our laboratory have demonstrated
that the administration of sildenafil into the left lateral
ventricle of conscious rats elicited a marked increase in the
lumbar sympathetic activity associated with tachycardia but
no change in the arterial pressure.1 The intracerebroven-
tricular administration of sildenafil may have produced
sympathetic overactivity in the spinal cord, thereby activat-
ing sympathetic preganglionic neurons (SPNs) in addition
to supraspinal areas, such as the rostral ventrola-
teral medulla, circumventricular organs (subfornical organ,
organum vasculosum lamina terminalis, and area postrema)
and hypothalamic sites controlling the sympathetic drive.2-5
Thus, the increase in lumbar sympathetic activity and
tachycardia observed in conscious rats following the
administration of sildenafil into the left lateral ventricle
may be explained by an effect in the spinal cord that is
probably mediated by SPN activation.1 Therefore, in order
to test the hypothesis that sildenafil is able to directly
activate the SPNs and cause a hemodynamic response, the
first goal of the present study was to examine, in conscious
rats, the effects of sildenafil on the mean arterial pressure
(MAP) and heart rate (HR) following intrathecal adminis-
tration.
Sildenafil increases intracellular cGMP levels via inhibition
of phosphodiesterase type 5 (PDE5).6-11 Moreover, sildenafil
can inhibit other phosphodiesterases, including those that
preferentially degrade cGMP, cAMP, or both depending on
the dose. The inhibition of phosphodiesterases leads to an
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increase in the intracellular cAMP level.12-15 In anesthetized
rats, a dose-dependent increase in the MAP following the
intrathecal administration of an cGMP analog (8-bromo-
cGMP) has been observed. A 8-bromo-cGMP-dependent
increase in theMAP suggests that the mechanism underlying
this increase involves cGMP.16
As the hemodynamic response caused by sildenafil may
involve a lack of cGMP degradation, the second goal of this
study was to evaluate the hemodynamic effects of the
intrathecal administration of 8-bromo-cGMP in conscious
rats and to compare the results with the sildenafil-induced
hemodynamic response. Moreover, several studies have
proposed that sildenafil, by itself, increases the levels of
cAMP.13-15 After taking this idea into account, the final
objective of the present study was to examine the
cardiovascular response of conscious rats following the
intrathecal administration of forskolin, a direct activator of
adenylate cyclase that increases the intracellular levels of
cAMP, and dibutyryl-cAMP, an analog of cAMP, and to
compare the results with the sildenafil-induced response.
MATERIAL AND METHODS
Animals
All experiments were performed on male Wistar rats
(320¡30 g) housed individually with free access to food
and water. The rats were maintained on a 12512 h light-
dark cycle. The experimental protocols used in this research
were approved by the Committee of Ethics in Animal
Research of the School of Medicine of Ribeira˜o Preto,
University of Sa˜o Paulo (protocol 199/2008).
Surgical procedures
The rats were anesthetized with tribromoethanol
(250 mg/kg, i.p., Sigma Aldrich) and underwent a two-
stage surgery. Initially, a polyethylene cannula PE-10
(,15 cm long, total volume 10 mL) filled with heparinized
saline (pH 7.4) was inserted through the intervertebral
space (L5-L6) into the spinal subarachnoid space in a
cranial direction (2 cm). The cannula was then implanted
using the method reported by Prado et al.17 with a slight
modification developed by Storkson et al.18 Once the
procedure was completed, the animals were allowed five
days to recover. On the day before the experiment,
polyethylene tubing was inserted into the left femoral
artery for direct measurement of the arterial pressure. The
experiments were performed in conscious rats 24 hours
after femoral artery catheterization.
Measurement of arterial pressure
During the experiments, silence was maintained to avoid
undue stress on the animals. The pulsatile arterial pressure
was recorded by connecting the arterial catheter to a
pressure transducer (P23Gb, Statham, Hato Hey, PR) and
was continuously sampled (2 kHz) using an IBM/PC
equipped with an analog-to-digital interface (DI-220 Dataq
Instruments, Akron, OH). The pulsatile arterial pressure
recordings were then analyzed using the CODAS software
(Dataq Instruments, Akron, OH) to obtain the MAP and HR
values.
Experimental protocols
The animals received an single intrathecal dose (10 mL)
of sildenafil (100 mg, n = 7; 10 mg, n = 6; 1 mg, n = 4; 0.1 mg,
n = 3), 8-bromo-cGMP (0.03 mg, n = 3; 0.47 mg, n = 6; 1.4 mg,
n = 7), forskolin (100 mg, n = 7), dibutyryl-cAMP (100 mg,
n = 4) or vehicle (1% DMSO, n = 6). The drugs and vehicle
(10 mL) were administered via the intrathecal cannula
using a Hamilton microsyringe. After drug administra-
tion, an additional 10 mL of aCSF was injected to clear the
catheter of the drug solution. At the end of the experi-
ment, 10 mL of Evan’s blue was injected into the
subarachnoid space. The rats were then anesthetized with
tribromoethanol (250 mg/kg, i.p.) and perfused through
the heart with 4% paraformaldehyde in 0.1 M phosphate
buffered saline. Finally, a necropsy was performed to
confirm the position of the intrathecal catheter and to
determine how far the dye spread within the subarach-
noid space.17,19
Drugs
The drugs used in the current study were sildenafil citrate
(Pfizer), 8-bromo-cGMP (8-bromoguanosine 39,59-cyclico-
monophosphate sodium salt), dibutyryl-cAMP (N6,29-O-
dibutyryladenosine 39,59-cyclic monophosphate sodium
salt), and forskolin (Sigma-Aldrich). The vehicle used was
DMSO (dimethyl sulfoxide). The components of the aCSF
were 127 mM NaCl, 1.9 mM KCl, 1.2 mM KH2PO4, 2.4 mM
CaCl2, 1.3 mM MgSO4, 26 mM NaHCO3 and 10 mM D-
glucose (Sigma-Aldrich). All drugs were dissolved in 1%
DMSO immediately before administration, and the pH of
the drug solutions was adjusted to 7.4.
Statistical analysis
The results are expressed as the mean ¡ SEM.
Comparisons were performed using one-way and two-
way analysis of variance (ANOVA) tests followed by a post-
hoc Newman-Keuls test. The statistical differences were
considered significant at p,0.05.
RESULTS
Basal MAP and HR.
The baseline MAP and HR in rats that received an
intrathecal administration of sildenafil, 8-bromo-cGMP,
forskolin, dibutyryl-cAMP, or vehicle (DMSO) were similar
(Table 1).
Effects of intrathecal administration of sildenafil on
the MAP and HR
Intrathecal sildenafil administration elicited a dose-
dependent increase in the MAP and HR (Figure 1).
Although the maximal pressor and tachycardic response
induced by 100 and 10 mg of sildenafil were similar, there
was a considerable delay in the maximal response with the
lower dose.
Table1 - Basal hemodynamic data of conscious rats.
MAP (mm Hg) HR (bpm)
DMSO 108¡3 386¡14
Sildenafil 101¡3 378¡6
8-Bromo-cGMP 104¡2 381¡6
Forskolin 106¡2 375¡6
Dibutyryl-cAMP 103¡7 379¡16
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Effects of intrathecal administration of 8-bromo-
cGMP on the MAP and HR.
The intrathecal administration of different doses of the
membrane-permeable analogue of cGMP, 8-bromo-cGMP or
its vehicle, DMSO, did not affect the MAP or HR (Figure 2).
Effects of intrathecal administration of forskolin
and dibutyryl-cAMP on the MAP and HR.
The administration of forskolin did not affect the MAP
but did increase the HR, while the membrane-permeable
cAMP analog, dibutyryl-cAMP, induced a rapid and
significant increase in both the MAP and HR (Figure 3).
DISCUSSION
The major findings of this study indicate that the
intrathecal administration of sildenafil in conscious rats
results in a dose-dependent increase in the MAP combined
with tachycardia that is unrelated to cGMP action as the
administration of a cGMP analog (8-bromo-cGMP) had no
effect. In addition, a direct activator of adenylate cyclase
(forskolin) increased the HR but did not affect the MAP. In
contrast, a cAMP analog (dibutyryl-cAMP) increased the
MAP and HR, similar to the increase observed following the
administration of 100 mg sildenafil.
One possible explanation for the results observed follow-
ing the intrathecal administration of sildenafil is the
activation of SPNs located in the intermediolateral column
of the spinal cord that predominantly innervate the heart
and blood vessels. The hemodynamic response obtained
with 10 and 1 mg of sildenafil indirectly support this
hypothesis, as the increase in the MAP and HR was delayed
when compared to results observed after the administration
of 100 mg of the drug. The magnitude of the hemodynamic
response was comparable even though the doses differed. A
possible explanation for this delay may be that lower doses
Figure 1 - Time course of the mean arterial pressure (DMAP) and heart rate (D HR) induced by the intrathecal administration of 100 mg
(A), 10 mg (B), 1 mg (C), or 0.1 mg (D) sildenafil or the vehicle (DMSO). *p,0.05 compared to DMSO.
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of sildenafil require a longer time to achieve the effective
concentration required for the activation of SPNs located
deep inside the spinal cord. In fact, an increase in
sympathetic activity has been observed in humans after
only a single dose of sildenafil.20,21 In addition, a study
recently conducted in our laboratory1 has indicated that the
intracerebroventricular administration of sildenafil in rats
causes a noticeable increase in lumbar sympathetic activity
without an accompanying change in the MAP.
To fully understand the implications for human health,
the hemodynamic effects caused by the intrathecal admin-
istration of sildenafil in conscious rats observed in this study
necessitate comparison with similar studies in humans. In a
study by Philips et al.20 in which healthy males received oral
sildenafil, sildenafil had no effect on the MAP and HR but
did elicit a significant increase in muscle sympathetic nerve
activity. Despite the absence of hemodynamic changes
(arterial pressure and heart rate), the findings of the
previous researchers20 demonstrate that sildenafil was able
to promote sympathetic activation. However, a study
recently conducted by our laboratory1 demonstrated that
intracerebroventricular administration of sildenafil (100 mg/
5 mL) results in a noticeable increase in lumbar sympathetic
activity without an accompanying change in the MAP. This
contrasts with the significant tachycardia observed in the
aforementioned Philips study.20
In the current study, the MAP and HR were unaffected by
the intrathecal administration of increasing doses of 8-
bromo-cGMP. Conversely, Malik et al.16 performed intrathe-
cal administration of 8-bromo-cGMP in anesthetized rats,
with the same doses used in the present study, and
observed a dose-dependent increase in the MAP.
However, it should be noted that the results of the current
study were obtained using conscious rats, without the use of
anesthesia and its associated detrimental effects. One
possible explanation for the absence of any cardiovascular
effects following the 8-bromo-cGMP injection is that this
compound can act directly on high conductance potassium
channels in the cell membrane, thereby promoting hyper-
polarization of the cell and decreasing their excitability.22
Therefore, the possible excitatory effect of 8-bromo-cGMP
could be antagonized by its direct action on potassium
channels, masking any possible activation of SPNs and
blunting the hemodynamic response. Finally, it is reason-
able to hypothesize that the increase in the MAP and HR
caused by the intrathecal administration of sildenafil are not
mediated by cGMP. There is evidence that sildenafil can
interfere with cAMP activity and inhibit the activity of other
PDEs.12-15 It is well known that drug selectivity, dose and
route of administration, distribution, pharmacokinetics and
the extent of activation of the NO-cGMP pathway are
important mechanisms determining the functional role of
sildenafil.23 Bischoff12 observed that sildenafil has different
inhibitory activity against the 11 families of PDEs. It is
possible that the dose of sildenafil used in the present study
inhibited not only PDE5 but also other PDEs, including
those PDEs that preferentially degrade cGMP, cAMP, or
both. Therefore, the additional treatments used in the
current study aimed to verify a possible role of cAMP in
the hemodynamic response promoted by sildenafil. To
accomplish this, the rats were intrathecally injected with a
direct activator of adenylate cyclase (forskolin) or a
membrane-permeable analogue of cAMP (dibutyryl-
cAMP). The intrathecally injected forskolin had no effect
on the MAP but increased the HR. However, the intrathe-
cally injected dibutyryl-cAMP increased the MAP and the
HR, an effect similar to sildenafil, suggesting that cAMP
may be involved in the mechanism underlying the
Figure 2 - Time course of the mean arterial pressure (DMAP) and heart rate (D HR) following the intrathecal administration of different
doses of the cGMP analog 8-bromo-cGMP or the vehicle (DMSO).
Figure 3 - Time course of the mean arterial pressure (D MAP) and heart rate (D HR) following the intrathecal administration of an
adenylate cyclase agonist (forskolin), a cAMP analog (dibutyryl-cAMP) or the vehicle (DMSO). *p,0.05 compared to DMSO.
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cardiovascular effects of sildenafil. Uckert et al.14 observed
that both forskolin and sildenafil administered indepen-
dently caused the relaxation of isolated human corpus
cavernosum tissue. However, this effect was reversed by
PKA-I (a cAMP-dependent kinase inhibitor) and PKG-I (a
cGMP-dependent kinase inhibitor) in both cases. These
findings suggest that cross-regulation may exist between the
cyclic nucleotides cAMP and cGMP. The results of the
current study are in line with those of Stief et al.,24 who
observed that the administration of increasing concentra-
tions of sildenafil in isolated human corpus cavernosum
tissue did not modify the cGMP levels in the tissue,
although it did increase the cAMP levels. Similarly,
increasing concentrations of sildenafil administered to
isolated human heart muscle did not alter the cGMP levels,
although an increase in the cAMP levels was evident.24 In
addition, the findings of Stief et al.24 demonstrate that
milrinone, a PDE3-specific inhibitor, causes an increase in
the intracellular cAMP levels without altering the cGMP
levels, as PDE3 preferentially degrades cAMP. In addition,
Botha et al.25 verified that while the serum levels of cAMP
increase after the administration of two different doses of
sildenafil and milrinone, the serum levels of cGMP are not
altered.
Overall, the results of the current study strongly suggest
that the pressor response and tachycardia observed after the
intrathecal administration of sildenafil to conscious rats
involves the inhibition of non-PDE5, cAMP-increasing
phosphodiesterases that activate sympathetic preganglionic
neurons. The hemodynamic response elicited by the
intrathecal administration of sildenafil to conscious, freely
moving rats may aid in understanding the cardiovascular
outcomes associated with the clinical use of this drug.
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